A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

D. H. Lee, A. Roohullah,B. C. Cho,S-H. Lee, C. Lemech,P. De Souza, M. Millward,J. Choi,K. E. Park, E. Kim,N. Y. Kim, Y. K. Shin,J-Y. Han

Annals of Oncology(2022)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要